Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418406 | 0.92 | CACNA1G (0.50) | CACNA1GMEN1KMT2AHDAC6BRD4 | |
| SCHEMBL7977871 | 0.89 | HDAC6 (0.49) | CACNA1GMEN1KMT2AHDAC6BRD4 | |
| SCHEMBL7974402 | 0.89 | CACNA1G (0.48) | CACNA1GMEN1KMT2AHDAC6MAPT | |
| SCHEMBL6766445 | 0.88 | MMP13 (0.55) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL7981151 | 0.87 | CACNA1G (0.48) | CACNA1GMEN1KMT2AHDAC6ALDH1A1 | |
| SCHEMBL1417419 | 0.87 | KMT2A (0.53) | CACNA1GMEN1KMT2AHDAC6ALDH1A1 | |
| SCHEMBL7979501 | 0.85 | L3MBTL1 (0.53) | CACNA1GMEN1KMT2AHDAC6ALDH1A1 | |
| SCHEMBL1418031 | 0.85 | DRD4 (0.55) | CACNA1GMEN1KMT2AHDAC6BRD4 | |
| SCHEMBL7994912 | 0.84 | ALDH1A1 (0.54) | CACNA1GBRD4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7983775 | 0.82 | MEN1 (0.45) | CACNA1GMEN1KMT2AHDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | CACNA1G 1733/4885MEN1 2484/4885KMT2A 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.